Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis - Seite 3
About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best
meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net
sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies
employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
For Novartis multimedia content, please visit www.novartis.com/news/media-library. For questions about the
site or required registration, please contact: media.relations@novartis.com
# # #
Novartis Media Relations
Central media line : +41 61 324 2200 | |
Paul Barrett Novartis External Communications +41 61 324 5224 (direct) +41 79 797 8137 (mobile) paul.barrett@novartis.com |
Eric Althoff Novartis Global Media Relations +1 212 830 2408 (direct) +1 646 438 4335 (mobile) eric.althoff@novartis.com |
e-mail: media.relations@novartis.com
Lesen Sie auch
Novartis Investor Relations
Central phone: | +41 61 324 7944 | ||
Samir Shah | +41 61 324 7944 | North America: | |
Pierre-Michel Bringer | +41 61 324 1065 | Richard Pulik | +1 212 830 2448 |
Thomas Hungerbuehler | +41 61 324 8425 | Sloan Pavsner | +1 212 830 2417 |
Isabella Zinck | +41 61 324 7188 | ||
e-mail: investor.relations@novartis.com | e-mail: investor.relations@novartis.com |